KRAS G12C inhibitor HYP-2090PTSA

An orally bioavailable inhibitor of the oncogenic KRAS substitution mutation G12C, with potential antineoplastic activity. Upon oral administration, KRAS G12C inhibitor HYP-2090PTSA selectively targets the KRAS G12C mutant and inhibits KRAS G12C-mediated signaling. This may halt proliferation and metastasis in KRAS G12C mutated tumor cells. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell proliferation, invasion, and metastasis. HYP-2090PTSA may also inhibit phosphatidylinositol 3-kinase (PI3K) activity and PI3K/Akt (protein kinase B)-mediated signaling pathway.